Étiquette : publi

Andrés, M., Werf, M. J. van der, Ködmön, C., Albrecht, S., Haas, W., Fiebig, L. and Group, S. study (2019). Molecular and genomic typing for tuberculosis surveillance: A survey study in 26 European countries. PLOS ONE 14, e0210080, http://doi.org/10.1371/journal.pone.0210080.

Aubry, A. and Veziris, N. (2019). Smear Microscopy Complements Xpert MTB/RIF When Considering Nontuberculous Mycobacterial Infections. Am J Respir Crit Care Med 200, 1072–1073, http://doi.org/10.1164/rccm.201905-0965LE.

Baron, V., Forfait, C., Colot, J., Carzola, C., Descloux, E., Cauchoix, B., Cambau, E., Gaumery, J., Grangeon, J. and Klement, E. (2019). Épidémiologie de la lèpre en Nouvelle-Calédonie de 1983 à 2017. BEH 400–405, URL: https://www.santepubliquefrance.fr/import/epidemiologie-de-la-lepre-en-nouvelle-caledonie-de-1983-a-2017 [Accessed February 2022].

Bouziane, F., Allem, R., Sebaihia, M., Kumanski, S., Mougari, F., Sougakoff, W., Raskine, L., Yala, D. and Cambau, E. (2019). First genetic characterisation of multidrug-resistant Mycobacterium tuberculosis isolates from Algeria. Journal of Global Antimicrobial Resistance 19, 301–307, http://doi.org/10.1016/j.jgar.2019.05.010.

Daniau, C., Lecorché, E., Mougari, F. and et al. (2019). Infections invasives à Mycobacterium chimaera en chirurgie cardiaque et évaluation des pratiques autour des matériels de circulation extracorporelle. Hygienes 27, 351–359, http://doi.org/10.25329/hy_xxvii_6-1.

Decalonne, M., Lecorche, E., Hau, E., Petiteau, A., Moreau, C., Milan, O., Lanotte, P., Mereghetti, L., Cambau, E. and van der Mee-Marquet, N. (2019). Cause Analysis of an Infection in Facelift Surgery Due to Mycobacterium chelonae. Frontiers in Medicine 6, URL: https://www.frontiersin.org/article/10.3389/fmed.2019.00243 [Accessed February 2022].

Dutertre, M., Delobel, P., Marchou, B., Boyer, J.-F., Mougari, F. and Martin-Blondel, G. (2019). Olecranon bursitis secondary to Mycobacterium europaeum infection in a patient receiving immunosuppressive drugs for rheumatoid arthritis. Médecine et Maladies Infectieuses 49, 358–359, http://doi.org/10.1016/j.medmal.2019.03.002.

Guglielmetti, L., Jaffré, J., Bernard, C., Brossier, F., El Helali, N., Chadelat, K., Thouvenin, G., Dautzenberg, B., Henry, B., Jaspard, M., Guillot, H., Pourcher, V., Le Dû, D., Marigot-Outtandy, D., Mougari, F., Raskine, L., Rivoire, B., Andrejak, C., Jarlier, V., Aubry, A., Robert, J., Frechet-Jachym, M. and Veziris, N. (2019). Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium. The International Journal of Tuberculosis and Lung Disease 23, 1050–1054, http://doi.org/10.5588/ijtld.18.0779.

Guglielmetti, L., Sougakoff, W., Maitre, T., Brossier, F., Jarlier, V., Robert, J., Veziris, N. and Aubry, A. (2019). Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen. Clinical Infectious Diseases 68, 1410–1411, http://doi.org/10.1093/cid/ciy808.

Mbuagbaw, L., Guglielmetti, L., Hewison, C., Bakare, N., Bastard, M., Caumes, E., Fréchet-Jachym, M., Robert, J., Veziris, N., Khachatryan, N., Kotrikadze, T., Hayrapetyan, A., Avaliani, Z., Schünemann, H. J. and Lienhardt, C. (2019). Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis. Emerg Infect Dis 25, http://doi.org/10.3201/eid2505.181823.

Perrineau, S., Lachâtre, M., Lê, M. P., Rioux, C., Loubet, P., Fréchet-Jachym, M., Gonzales, M. C., Grall, N., Bouvet, E., Veziris, N., Yazdanpanah, Y. and Peytavin, G. (2019). Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis. Int J Tuberc Lung Dis 23, 99–104, http://doi.org/10.5588/ijtld.18.0042.

Petrella, S., Capton, E., Raynal, B., Giffard, C., Thureau, A., Bonneté, F., Alzari, P. M., Aubry, A. and Mayer, C. (2019). Overall Structures of Mycobacterium tuberculosis DNA Gyrase Reveal the Role of a Corynebacteriales GyrB-Specific Insert in ATPase Activity. Structure 27, 579-589.e5, http://doi.org/10.1016/j.str.2019.01.004.

Rodriguez, C. A., Brooks, M. B., Guglielmetti, L., Hewison, C., Jachym, M. F., Lessem, E., Varaine, F. and Mitnick, C. D. (2019). Barriers and facilitators to early access of bedaquiline and delamanid for MDR-TB: a mixed-methods study. Public Health Action 9, 32–41, http://doi.org/10.5588/pha.18.0078.

Rollet-Cohen, V., Roux, A.-L., Bourgeois, M. L., Sapriel, G., Bahri, M. E., Jais, J.-P., Heym, B., Mougari, F., Raskine, L., Véziris, N., Gaillard, J.-L. and Sermet-Gaudelus, I. (2019). Mycobacterium bolletii lung disease in cystic fibrosis. CHEST 0, http://doi.org/10.1016/j.chest.2019.03.019.

Sane Schepisi, M., Navarra, A., Altet Gomez, M. N., Dudnyk, A., Dyrhol-Riise, A. M., Esteban, J., Giorgetti, P. F., Gualano, G., Guglielmetti, L., Heyckendorf, J., Kaluzhenina, A., Lange, B., Lange, C., Manika, K., Miah, J., Nanovic, Z., Pontali, E., Prego, M. R., Solovic, I., Tiberi, S., Palmieri, F. and Girardi, E. (2019). Burden and Characteristics of the Comorbidity Tuberculosis—Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study. Open Forum Infectious Diseases 6, ofy337, http://doi.org/10.1093/ofid/ofy337.

van Leth, F., Brinkmann, F., Cirillo, D. M., Dheda, K., Duarte, R., Guglielmetti, L., Kuksa, L., Lange, C., Mitnick, C., Skrahina, A., Zaman, K. and Bothamley, G. (2019). The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation. European Respiratory Journal 53, http://doi.org/10.1183/13993003.02089-2018.

Avanzi, C., Lécorché, E., Rakotomalala, F. A., Benjak, A., Rapelanoro Rabenja, F., Ramarozatovo, L. S., Cauchoix, B., Rakoto-Andrianarivelo, M., Tió-Coma, M., Leal-Calvo, T., Busso, P., Boy-Röttger, S., Chauffour, A., Rasamoelina, T., Andrianarison, A., Sendrasoa, F., Spencer, J. S., Singh, P., Dashatwar, D. R., Narang, R., Berland, J.-L., Jarlier, V., Salgado, C. G., Moraes, M. O., Geluk, A., Randrianantoandro, A., Cambau, E. and Cole, S. T. (2020). Population Genomics of Mycobacterium leprae Reveals a New Genotype in Madagascar and the Comoros. Frontiers in Microbiology 11, URL: https://www.frontiersin.org/article/10.3389/fmicb.2020.00711 [Accessed March 2022].

BRUUT! (2020). Loulou. 6 March 2020, URL: https://www.youtube.com/watch?v=jPwFWmY271A [Accessed October 2022].

Cambau, E. and Poljak, M. (2020). Sniffing animals as a diagnostic tool in infectious diseases. Clinical Microbiology and Infection 26, 431–435, http://doi.org/10.1016/j.cmi.2019.10.036.

Chauffour, A., Robert, J., Veziris, N., Aubry, A., Pethe, K. and Jarlier, V. (2020). Telacebec (Q203)-containing intermittent oral regimens sterilized mice infected with Mycobacterium ulcerans after only 16 doses. PLOS Neglected Tropical Diseases 14, e0007857, http://doi.org/10.1371/journal.pntd.0007857.

Cox, V., McKenna, L., Acquah, R., Reuter, A., Wasserman, S., Vambe, D., Ustero, P., Udwadia, Z., Triviño-Duran, L., Tommasi, M., Skrahina, A., Seddon, J. A., Rodolfo, R., Rich, M., Padanilam, X., Oyewusi, L., Ohler, L., Lungu, P., Loveday, M., Khan, U., Khan, P., Hughes, J., Hewison, C., Guglielmetti, L. and Furin, J. (2020). Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB. The International Journal of Tuberculosis and Lung Disease 24, 1134–1144, http://doi.org/10.5588/ijtld.20.0330.

Daley, C. L., Iaccarino, J. M., Lange, C., Cambau, E., Wallace, R. J., Jr, Andrejak, C., Böttger, E. C., Brozek, J., Griffith, D. E., Guglielmetti, L., Huitt, G. A., Knight, S. L., Leitman, P., Marras, T. K., Olivier, K. N., Santin, M., Stout, J. E., Tortoli, E., van Ingen, J., Wagner, D. and Winthrop, K. L. (2020). Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clinical Infectious Diseases 71, e1–e36, http://doi.org/10.1093/cid/ciaa241.

Guglielmetti, L., Low, M. and McKenna, L. (2020). Challenges in TB regimen development: preserving evidentiary standards for regulatory decisions and policymaking. Expert Review of Anti-infective Therapy 18, 701–704, http://doi.org/10.1080/14787210.2020.1756776.

Guglielmetti, L., Huerga, H., Khan, U. and Varaine, F. (2020). WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion? Eur Respir J 55, 1901935, http://doi.org/10.1183/13993003.01935-2019.

Guglielmetti, L., Chiesi, S., Eimer, J., Dominguez, J., Masini, T., Varaine, F., Veziris, N., Ader, F. and Robert, J. (2020). Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician’s perspective. Future Microbiology 15, 779–799, http://doi.org/10.2217/fmb-2019-0309.

Jaffré, J., Aubry, A., Maitre, T., Morel, F., Brossier, F., Robert, J., Sougakoff, W., Veziris, N. and the CNR-MyRMA (Centre National de Référence des Mycobactéries et de la Résistance des Mycobactéries aux Antituberculeux) (2020). Rational Choice of Antibiotics and Media for Mycobacterium avium Complex Drug Susceptibility Testing. Frontiers in Microbiology 11, URL: https://www.frontiersin.org/article/10.3389/fmicb.2020.00081 [Accessed March 2022].

Jaspard, M., Butel, N., Helali, N. E., Marigot-Outtandy, D., Guillot, H., Peytavin, G., Veziris, N., Bodaghi, B., Flandre, P., Petitjean, G., Caumes, E. and Pourcher, V. (2020). Linezolid-Associated Neurologic Adverse Events in Patients with Multidrug-Resistant Tuberculosis, France. Emerg Infec Dis 26, http://doi.org/10.3201/eid2608.191499.

Kort, F., Ray, L. F. L., Chauffour, A., Jarlier, V., Lounis, N., Andries, K., Aubry, A., Guglielmetti, L. and Veziris, N. (2020). Fully weekly antituberculosis regimen: a proof-of-concept study. European Respiratory Journal 56, http://doi.org/10.1183/13993003.02502-2019.

Lan, Zhiyi, Ahmad, Nafees, Baghaei, Parvaneh, Barkane, Linda, Benedetti, Andrea, Brode, Sarah K., Brust, James C. M., Campbell, Jonathon R., Chang, Vicky Wai Lai, Falzon, Dennis, Guglielmetti, Lorenzo, Isaakidis, Petros, Kempker, Russell R., Kipiani, Maia, Kuksa, Liga, Lange, Christoph, Laniado-Laborín, Rafael, Nahid, Payam, Rodrigues, Denise, Singla, Rupak, Udwadia, Zarir F., Menzies, Dick, Ahmad, N., Baghaei, P., Barkane, L., Benedetti, A., Brode, S. K., Brust, J. C. M., Campbell, J. R., Chang, V. W. L., Falzon, D., Guglielmetti, L., Isaakidis, P., Kempker, R. R., Kipiani, M., Kuksa, L., Lan, Z., Lange, C., Laniado-Laborín, R., Nahid, P., Rodrigues, D., Singla, R., Udwadia, Z. F. and Menzies, D. (2020). Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet Respiratory Medicine 8, 383–394, http://doi.org/10.1016/S2213-2600(20)30047-3.

Lecorche, E., Pean de Ponfilly, G., Mougari, F., Benmansour, H., Poisnel, E., Janvier, F. and Cambau, E. (2020). Disseminated Mycobacterium chimaera Following Open-Heart Surgery, the Heater–Cooler Unit Worldwide Outbreak: Case Report and Minireview. Frontiers in Medicine 7, URL: https://www.frontiersin.org/article/10.3389/fmed.2020.00243 [Accessed March 2022].

Lerolle, N., Laanani, M., Galicier, L., Rivière, S., Meynard, J.-L., Azoulay, E., Jeblaoui, A., Lalande, V., Mougari, F., Fardet, L., Coppo, P., Goujard, C., Molina, J.-M. and Lambotte, O. (2020). Factors associated with tuberculosis-associated haemophagocytic syndrome: a multicentre case-control study. The International Journal of Tuberculosis and Lung Disease 24, 124–130, http://doi.org/10.5588/ijtld.19.0856.

Lopes, A., Mougari, F., Chopin, D., Pogliaghi, M., Munier, A., Delcey, V., Simoneau, G., Raskine, L., Evans, J., Mouly, S., Cambau, E., Bergmann, J. and Sellier, P. (2020). Prospective study comparing the conventional and same-day strategies to diagnose pulmonary tuberculosis - ScienceDirect. Med Mal Infect 50, 36–42, URL: https://www.sciencedirect.com/science/article/pii/S0399077X18301343?via%3Dihub [Accessed March 2022].

Marsollier, L., Aubry, A., Carbonnelle, E., Canaan, S., Laencina, L., Cambau, E. and Herrmann, J. (2020). Mycobactérioses cutanées dues à Mycobacterium ulcerans, Mycobacterium marinum, Mycobacterium abscessus, Mycobacterium chelonae et autres mycobactéries non tuberculeuses. EM-Consulte, http://doi.org/10.1016/S1166-8598(19)81974-9.

Méchaï, F., Cordel, H., Guglielmetti, L., Aubry, A., Jankovic, M., Viveiros, M., Santin, M., Goletti, D. and Cambau, E. (2020). Management of Tuberculosis: Are the Practices Homogeneous in High-Income Countries? Frontiers in Public Health 8, URL: https://www.frontiersin.org/article/10.3389/fpubh.2020.00443 [Accessed March 2022].

Morel, F., Jaffré, J., Sougakoff, W., Aubry, A. and Véziris, N. (2020). Place de la biologie moléculaire dans le diagnostic de la tuberculose. Revue des Maladies Respiratoires 37, 412–416, http://doi.org/10.1016/j.rmr.2019.09.004.

Ong, C. W. M., Migliori, G. B., Raviglione, M., MacGregor-Skinner, G., Sotgiu, G., Alffenaar, J.-W., Tiberi, S., Adlhoch, C., Alonzi, T., Archuleta, S., Brusin, S., Cambau, E., Capobianchi, M. R., Castilletti, C., Centis, R., Cirillo, D. M., D’Ambrosio, L., Delogu, G., Esposito, S. M. R., Figueroa, J., Friedland, J. S., Ho, B. C. H., Ippolito, G., Jankovic, M., Kim, H. Y., Klintz, S. R., Ködmön, C., Lalle, E., Leo, Y. S., Leung, C.-C., Märtson, A.-G., Melazzini, M. G., Fard, S. N., Penttinen, P., Petrone, L., Petruccioli, E., Pontali, E., Saderi, L., Santin, M., Spanevello, A., Crevel, R. van, Werf, M. J. van der, Visca, D., Viveiros, M., Zellweger, J.-P., Zumla, A. and Goletti, D. (2020). Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of Clinical Microbiology and Infectious Diseases Study Group for Mycobacterial Infections (ESGMYC). European Respiratory Journal 56, http://doi.org/10.1183/13993003.01727-2020.

Phillips, R. O., Robert, J., Abass, K. M., Thompson, W., Sarfo, F. S., Wilson, T., Sarpong, G., Gateau, T., Chauty, A., Omollo, R., Ochieng Otieno, M., Egondi, T. W., Ampadu, E. O., Agossadou, D., Marion, E., Ganlonon, L., Wansbrough-Jones, M., Grosset, J., Macdonald, J. M., Treadwell, T., Saunderson, P., Paintsil, A., Lehman, L., Frimpong, M., Sarpong, N. F., Saizonou, R., Tiendrebeogo, A., Ohene, S.-A., Stienstra, Y., Asiedu, K. B., van der Werf, T. S., Osei Mireku, S., Abotsi, J., Adu Poku, J. K., Asamoah-Frimpong, R., Osei-Wusu, B., Sarpong, E., Konadu, B., Opoku, E., Forson, M., Ndogyele, M., Ofori, E., Aboagye, F., Berko, T., Amofa, G., Nsiah, A., Mensah-Bonsu, J., Ofori Nyarko, J., Amoako, Y. A., Koranteng Tannor, E., Boakye-Appiah, J., Dzibordzi Loglo, A., Sarpong-Duah, M., Agbavor, B., Ardent, M. F., Yamadjako, A., Adanmado Gersande, N., Adeye, A., Kindjinou, M., Akpolan, Kiki, M., Sodjinou, E., Guegnard, C., Klis, S.-A., Velding, K., Omansen, T., Ofori-Adjei, D., Eyangoh, S., Knell, A. and Faber, W. (2020). Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial. The Lancet 395, 1259–1267, http://doi.org/10.1016/S0140-6736(20)30047-7.

Rousset, L., Sokal, A., Vignon-Pennamen, M.-D., Pagis, V., Rybojad, M., Lecorche, E., Mougari, F., Bagot, M., Bouaziz, J.-D. and Jachiet, M. (2020). Association d’une lèpre borderline tuberculoïde et d’une tuberculose : un cas et revue de la littérature. Annales de Dermatologie et de Vénéréologie 147, 886–891, http://doi.org/10.1016/j.annder.2020.09.571.

Schön, T., Köser, C. U., Werngren, J., Viveiros, M., Georghiou, S., Kahlmeter, G., Giske, C., Maurer, F., Lina, G., Turnidge, J., Ingen, J. van, Jankovic, M., Goletti, D., Cirillo, D. M., Santin, M. and Cambau, E. (2020). What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex? Clinical Microbiology and Infection 26, 1453–1455, http://doi.org/10.1016/j.cmi.2020.07.037.

Schön, T., Werngren, J., Machado, D., Borroni, E., Wijkander, M., Lina, G., Mouton, J., Matuschek, E., Kahlmeter, G., Giske, C., Santin, M., Cirillo, D. M., Viveiros, M. and Cambau, E. (2020). Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex isolates – the EUCAST broth microdilution reference method for MIC determination. Clinical Microbiology and Infection 26, 1488–1492, http://doi.org/10.1016/j.cmi.2020.07.036.

Bachir, M., Guglielmetti, L., Tunesi, S., Billard-Pomares, Typhaine, Chiesi, S., Jaffré, J., Langris, H., Pourcher, V., Schramm, F., Lemaître, N., Robert, J., Bouchaud, O., Billard-Pomares, T., Carbonnelle, E., Mechaï, F., Nunes, H., Pellan, M., Morin, A.-S., Dumesnil, C., Dumoulin, J., Roux, A.-L., Jachym, M., le Du, D., Marigot-Outtandy, D., Abgrall, S., Chambrin, V., Guillet, C., Fantin, B., Galy, A., Decousser, J.-W., Lelièvre, J. D., Gallien, S., Nebbad-Lechani, B., Deconinck, L., Bulifon, S., Fortineau, N., Wyplosz, B., Cohen, F., Lemaitre, N., Crestani, B., Grall, N., Pierre-Audigier, C., Rioux, C., Yazdanpanah, Y., Le Jeunne, C., Morand, P., Roche, N., Pavie, J., Loulergue, P., Delcey, V., Lecorché, E., Munier, A.-L., Mougari, F., Sellier, P., Bille, E., Ferroni, A., Guéry, R., Hummel, A., Lourenco, J., Aubry, A., Bonnet, I., Caumes, E., Londner, C., Morel, F., Lacombe, K., Lalande, V., Meynard, J.-L., Veziris, N., De Castro, N., Denis, B., Lafaurie, M., Molina, J.-M., Canestri, A., Lassel, L., Pialoux, G., Verdet, C., Nardi, A.-L., Gominet, M. and Catherinot, E. (2021). Isoniazid-monoresistant tuberculosis in France: Risk factors, treatment outcomes and adverse events. International Journal of Infectious Diseases 107, 86–91, http://doi.org/10.1016/j.ijid.2021.03.093.

Bemer, P., Peuchant, O., Guet-Revillet, H., Bador, J., Balavoine, C., Basille, D., Beltramo, G., Blanc, F.-X., Blanchard, E., Boulanger, S., Bourgoin, A., Boutoille, D., Cambau, E., Canis, F., Caparros, D., Carricajo, A., Carrière, C., Couetdic, G., Couturaud, F., Dalphin, J.-C., Degot, T., Desquiens, M., Devouassoux, G., Duez, J.-M., Dumitrescu, O., Dupuy-Grasset, M., Gaudart, A., Georges, M., Godet, C., Godreuil, S., Guillouzouic, A., Hamdad-Daoudi, F., Héry-Arnaud, G., Koebel, C., Lagrange, A., Lanotte, P., Marchand-Adam, S., Mougari, F., Murris, M., Patry, I., Pérouse de Montclos, M., Raskine, L., Risso, K., Segonds, C., Sicard, D., Terru, D., Vachée, A., Vergnon, J.-M., Martin, C., Schramm, F. and Andrejak, C. (2021). Management of patients with pulmonary mycobacteriosis in France: a multicenter retrospective cohort study. BMC Pulm Med 21, 1–9, http://doi.org/10.1186/s12890-021-01701-5.

Bonnet, I., Enouf, V., Morel, F., Ok, V., Jaffré, J., Jarlier, V., Aubry, A., Robert, J. and Sougakoff, W. (2021). A Comprehensive Evaluation of GeneLEAD VIII DNA Platform Combined to Deeplex Myc-TB® Assay to Detect in 8 Days Drug Resistance to 13 Antituberculous Drugs and Transmission of Mycobacterium tuberculosis Complex Directly From Clinical Samples. Front Cell Infect Microbiol 11, 707244, http://doi.org/10.3389/fcimb.2021.707244.

Calin, R., Belkacem, A., Caraux-Paz, P., Wagner, M., Guillot, H., Veziris, N., Jaureguiberry, S., Caumes, E., Patey, O. and Pourcher, V. (2021). Abdominal Tuberculosis: Experience from Two Tertiary-Care Hospitals in the Paris Region. The American Journal of Tropical Medicine and Hygiene 104, 223–228, http://doi.org/10.4269/ajtmh.20-0023.

Chauffour, A., Morel, F., Reibel, F., Petrella, S., Mayer, C., Cambau, E. and Aubry, A. (2021). A systematic review of Mycobacterium leprae DNA gyrase mutations and their impact on fluoroquinolone resistance. Clinical Microbiology and Infection 27, 1601–1612, http://doi.org/10.1016/j.cmi.2021.07.007.

Gies, V., Dieudonné, Y., Morel, F., Sougakoff, W., Carapito, R., Martin, A., Weingertner, N., Jacquel, L., Hubele, F., Kuhnert, C., Jung, S., Schramm, F., Boyer, P., Hansmann, Y., Danion, F., Korganow, A.-S. and Guffroy, A. (2021). Case Report: Acquired Disseminated BCG in the Context of a Delayed Immune Reconstitution After Hematological Malignancy. Front Immunol 12, 696268, http://doi.org/10.3389/fimmu.2021.696268.

Guglielmetti, L. and Varaine, F. (2021). The coming-of-age of bedaquiline: a tale with an open ending. European Respiratory Journal 57, http://doi.org/10.1183/13993003.00066-2021.

Guglielmetti, L., Ardizzoni, E., Atger, M., Baudin, E., Berikova, E., Bonnet, M., Chang, E., Cloez, S., Coit, J. M., Cox, V., de Jong, B. C., Delifer, C., Do, J. M., Tozzi, D. D. S., Ducher, V., Ferlazzo, G., Gouillou, M., Khan, A., Khan, U., Lachenal, N., LaHood, A. N., Lecca, L., Mazmanian, M., McIlleron, H., Moschioni, M., O’Brien, K., Okunbor, O., Oyewusi, L., Panda, S., Patil, S. B., Phillips, P. P. J., Pichon, L., Rupasinghe, P., Rich, M. L., Saluhuddin, N., Seung, K. J., Tamirat, M., Trippa, L., Cellamare, M., Velásquez, G. E., Wasserman, S., Zimetbaum, P. J., Varaine, F. and Mitnick, C. D. (2021). Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials 22, 651, http://doi.org/10.1186/s13063-021-05491-3.

Hewison, C. and Guglielmetti, L. (2021). Cardiac safety of multidrug-resistant tuberculosis treatment: moving towards individualised monitoring. Lancet Infect Dis 21, 894–895, http://doi.org/10.1016/S1473-3099(20)30836-7.

Lecorche, E., Daniau, C., La, K., Mougari, F., Benmansour, H., Kumanski, S., Robert, J., Fournier, S., Lebreton, G., Carbonne, A., Cambau, E. and CNR-MyRMA (2021). Mycobacterium chimaera Genomics With Regard to Epidemiological and Clinical Investigations Conducted for an Open Chest Postsurgical Mycobacterium chimaera Infection Outbreak. Open Forum Infectious Diseases 8, ofab192, http://doi.org/10.1093/ofid/ofab192.

Maitre, T., Guglielmetti, L. and Veziris, N. (2021). Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies. European Respiratory Journal 57, http://doi.org/10.1183/13993003.04315-2020.

Maitre, T., Ok, V., Morel, F., Bonnet, I., Sougakoff, W., Robert, J., Trosini, V., Caumes, E., Aubry, A. and Veziris, N. (2021). Sampling strategy for bacteriological diagnosis of intrathoracic tuberculosis. Respiratory Medicine and Research 79, 100825, http://doi.org/10.1016/j.resmer.2021.100825.

Mohamed, S., Köser, C. U., Salfinger, M., Sougakoff, W. and Heysell, S. K. (2021). Targeted next-generation sequencing: a Swiss army knife for mycobacterial diagnostics? European Respiratory Journal 57, http://doi.org/10.1183/13993003.04077-2020.

Molina‐Moya, B., Guglielmetti, L., Bothamley, G., van Leth, F., Lange, C., Dominguez, J. and TBnet Study Group (2021). Use and impact of molecular methods for detecting drug‐resistant TB. The International Journal of Tuberculosis and Lung Disease 25, 157–159, http://doi.org/10.5588/ijtld.20.0527.

Nyang’wa, B. T., LaHood, A. N., Mitnick, C. D. and Guglielmetti, L. (2021). TB research requires strong protections, innovation, and increased funding in response to COVID-19. Trials 22, 1–3, http://doi.org/10.1186/s13063-021-05331-4.

Ok, V., Aubry, A., Morel, F., Bonnet, I., Robert, J. and Sougakoff, W. (2021). Rapid Molecular Diagnosis of Tuberculosis and Its Resistance to Rifampicin and Isoniazid with Automated MDR/MTB ELITe MGB® Assay. Antibiotics 10, 797, http://doi.org/10.3390/antibiotics10070797.

Opota, O., Mazza-Stalder, J., Viveiros, M., Cambau, E., Santin, M. and Goletti, D. (2021). Editorial: Tuberculosis and Non-tuberculous Mycobacteria Infections: Control, Diagnosis and Treatment. Frontiers in Public Health 9, URL: https://www.frontiersin.org/article/10.3389/fpubh.2021.666187 [Accessed March 2022].

Ortuño-Gutiérrez, N., Mzembaba, A., Ramboarina, S., Andriamira, R., Baco, A., Braet, S., Younoussa, A., Cauchoix, B., Salim, Z., Amidy, M., Grillone, S., Rasamoelina, T., Cambau, E., Geluk, A., de Jong, B. C., Richardus, J. H. and Hasker, E. (2021). Exploring clustering of leprosy in the Comoros and Madagascar: A geospatial analysis. International Journal of Infectious Diseases 108, 96–101, http://doi.org/10.1016/j.ijid.2021.05.014.

Roelens, M., Battista Migliori, G., Rozanova, L., Estill, J., Campbell, J. R., Cegielski, J. P., Tiberi, S., Palmero, D., Fox, G. J., Guglielmetti, L., Sotgiu, G., Brust, J. C. M., Bang, D., Lienhardt, C., Lange, C., Menzies, D., Keiser, O. and Raviglione, M. (2021). Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. Am J Respir Crit Care Med 204, 713–722, http://doi.org/10.1164/rccm.202009-3527OC.

Schön, T., Werngren, J., Machado, D., Borroni, E., Wijkander, M., Lina, G., Mouton, J., Matuschek, E., Kahlmeter, G., Giske, C., Santin, M., Cirillo, D. M., Viveiros, M. and Cambau, E. (2021). Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis. Clinical Microbiology and Infection 27, 288.e1-288.e4, http://doi.org/10.1016/j.cmi.2020.10.019.

Starshinova, A., Guglielmetti, L., Rzhepishevska, O., Ekaterincheva, O., Zinchenko, Yu. and Kudlay, D. (2021). Diagnostics and management of tuberculosis and COVID-19 in a patient with pneumothorax (clinical case). J Clin Tuberc Other Mycobact Dis 24, 100259, http://doi.org/10.1016/j.jctube.2021.100259.

Tagliani, E., Anthony, R., Kohl, T. A., de Neeling, A., Nikolayevskyy, V., Ködmön, C., Maurer, F. P., Niemann, S., van Soolingen, D., van der Werf, M. J. and Cirillo, D. M. (2021). Use of a whole genome sequencing-based approach for Mycobacterium tuberculosis surveillance in Europe in 2017–2019: an ECDC pilot study. Eur Respir J 57, 2002272, http://doi.org/10.1183/13993003.02272-2020.

Veziris, N., Andréjak, C., Bouée, S., Emery, C., Obradovic, M. and Chiron, R. (2021). Non-tuberculous mycobacterial pulmonary diseases in France: an 8 years nationwide study. BMC Infect Dis 21, 1–10, http://doi.org/10.1186/s12879-021-06825-x.

Veziris, N., Bonnet, I., Morel, F., Guglielmetti, L., Maitre, T., Ray, L. F. L., Sougakoff, W., Robert, J. and Aubry, A. (2021). Impact of the revised definition of extensively drug-resistant tuberculosis. European Respiratory Journal 58, http://doi.org/10.1183/13993003.00641-2021.

World Health Organisation (2021). Technical Report on critical concentrations for drug susceptibility testing of isoniazid and the rifamycins (rifampicin, rifabutin and rifapentine), WHO, Geneva, URL: https://www.who.int/publications/i/item/technical-report-on-critical-concentrations-for-drugsusceptibility-testing-of-isoniazid-and-therifamycins-(rifampicin-rifabutin-and-rifapentine) [Accessed March 2022].